Somnomed Ltd

SomnoMed's capital structure shows a current ratio of 1.51, indicating moderate liquidity, with total liabilities of 34.58 million AUD and total equity of 46.39 million AUD. The company's liquidity position is further supported by an operating cash flow of 7.78 million AUD, though its free cash flow is negative at -1.69 million AUD, reflecting capital expenditures of -3.98 million AUD. The debt-to-equity ratio of 0.17 suggests a conservative leverage profile, with long-term debt at 8.03 million AUD. Profitability metrics reveal a challenging operating environment, with a net loss of 3.46 million AUD and an operating loss of 0.76 million AUD for the latest period. The company's return on equity is -7.45%, and return on assets is -4.27%, both significantly below the industry median for medical equipment firms. Gross profit of 66.75 million AUD represents a 59.9% margin, which is strong for a medical device company but insufficient to offset operating costs. Geographically, SomnoMed operates through five segments: North America, Europe, Asia Pacific, CORE, and RSS. Revenue concentration is not explicitly disclosed, but the company's international presence suggests exposure to multiple regional markets. The lack of detailed segment revenue data limits the ability to assess geographic risk or growth potential. The company's growth trajectory is mixed. While it reported revenue of 111.52 million AUD, the operating and net losses suggest operational inefficiencies or market pressures. Analysts have assigned a mean price target of 0.99 AUD, with a median of 0.99 AUD, and a mean recommendation of 1.67, indicating a generally positive outlook. However, the absence of a clear revenue growth rate or margin expansion in the latest financials raises questions about the sustainability of this optimism. Risk factors include a negative free cash flow and a net cash position that is negative after subtracting total debt, signaling potential liquidity constraints. The company's dilution risk is assessed as low, with no significant changes in shares outstanding between basic and diluted shares. However, the negative operating income and net loss suggest the company may need to raise capital in the future, which could lead to dilution. Recent events include the continued commercialization of the SomnoDent product line and the introduction of SomTabs for oral appliance cleaning. No recent filings or transcripts have been provided that indicate major strategic shifts or regulatory challenges.